The Correlation between the Change in Thoracic Fluid Content and the Change in Patient Body Weight in Fontan Procedure.

Biomed Res Int

Department of Anesthesiology and Pain Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea.

Published: October 2018

Background: The thoracic fluid content (TFC) and its percent change compared to the baseline (TFCd0%) derived from a bioreactance technique using a noninvasive cardiac output monitoring (NICOM) device correlate well with the amount of fluid removal in patients undergoing hemodialysis and with intraoperative fluid balance in pediatric patients undergoing cardiac surgery. We hypothesized that TFC or TFCd0% would also be a useful indicator allowing fluid management in pediatric patients undergoing a Fontan procedure.

Methods: The medical records of patients who underwent an elective Fontan procedure were reviewed retrospectively. The intraoperative variables recorded at two time points were used in the analysis: when the NICOM data obtained just after anesthesia induction (0) and just before transfer of the patient from the operating room to the ICU (1). The analyzed variables were hemodynamic parameters, TFC, TFCd0%, stroke volume variation, body weight gain, change in the central venous pressure, and difference in the TFC (ΔTFC).

Results: The correlation coefficient between TFCd0% and body weight gain was 0.546 ( = 0.01); between TFCd0% and body weight gain% 0.572 ( = 0.007); and between TFCd0% and intraoperative fluid balance 0.554 ( = 0.009). The coefficient of determination derived from a linear regression analysis of TFCd0% versus body weight gain was 0.30 ( = 0.01); between TFCd0% and body weight gain% 0.33 ( = 0.007); and between TFCd0% and intraoperative fluid balance 0.31 ( = 0.009).

Conclusions: TFCd0% correlated well with body weight gain, body weight gain%, and intraoperative fluid balance. It is a useful indicator in the intraoperative fluid management of pediatric patients undergoing a Fontan procedure.

Trial Registration: This trial is registered with Clinical Research Information Service KCT0002062.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966686PMC
http://dx.doi.org/10.1155/2018/3635708DOI Listing

Publication Analysis

Top Keywords

body weight
32
intraoperative fluid
20
patients undergoing
16
fluid balance
16
weight gain
16
pediatric patients
12
tfcd0% body
12
weight gain%
12
tfcd0%
10
fluid
9

Similar Publications

Effects of Ab501 (certolizumab mice equivalent) in arthritis induced bone loss.

ARP Rheumatol

January 2024

Instituto de Medicina Molecular-João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Portugal.

Introduction - Rheumatoid arthritis (RA) is a chronic immune-mediated inflammatory disease, which causes local and systemic bone damage. The main goal of this work was to analyze, how treatment intervention with Ab501 (certolizumab mice equivalent) prevents the disturbances on bone structure and mechanics induced by arthritis. Methods - Thirty DBA/1 collagen-induced arthritis (CIA) mice were randomly housed in experimental groups, as follows: arthritic untreated (N=9), preventive intervention (N=10) and treatment intervention (N=11).

View Article and Find Full Text PDF

The present study examined how individuals who have been clinically diagnosed as obese explain their decision to undergo bariatric surgery and how they deal with the stigmatization that such a decision may entail. A total of 23 participants (15 women and 8 men) who were awaiting bariatric surgery within the Spanish healthcare system, were interviewed about their weight trajectory and their decision to undergo this surgery. In order to examine the participants' stories, a narrative analysis of the interviews was conducted, with attention to both content ( they told) and structure ( they told) and examining the stories in line with the socially and culturally available narratives that they had access to, and the context in which the stories were produced.

View Article and Find Full Text PDF

Natural Products From Plants Targeting Leptin Resistance for the Future Development of Anti-Obesity Agents.

Phytother Res

January 2025

Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.

Obesity is a serious health threat, which has affected 16% of adults globally in 2022 and shows a trend toward youthfulness. Leptin, as a regulator of body weight, can suppress appetite and promote energy expenditure, making it potential in obesity treatment. Nevertheless, with the progress of relevant research, it is worth noting that monotherapy with leptin is not an effective strategy since most obese individuals are hyperleptinemic and resistant to leptin, where high levels of leptin fail to exert its weight-loss effects.

View Article and Find Full Text PDF

Wu-Mei-Wan enhances brown adipose tissue function and white adipose browning in obese mice via upregulation of HSF1.

Chin Med

January 2025

Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.

Background: This research aims to explore the anti-obesity potential of Wu-Mei-Wan (WMW), particularly its effects on adipose tissue regulation in obese mice induced by a high-fat diet (HFD). The study focuses on understanding the role of heat shock factor 1 (HSF1) in mediating these effects.

Methods: HFD-induced obese mice were treated with WMW.

View Article and Find Full Text PDF

The effects of the gut bacterial product, gassericin A, on obesity in mice.

Lipids Health Dis

January 2025

Department of Basic Sciences, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran.

Background: Obesity can arise from various physiological disorders. This research examined the impacts of the bacteriocin, gassericin A, which is generated by certain gut bacteria, using an in vivo model of obesity.

Methods: Fifty Swiss NIH mice were randomly assigned to five different groups.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!